Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q3 2025 on November 5, 2025, after the U.S. market closes, followed by a conference call to discuss these results [1]. Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes its Flow Electroporation technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to empower researchers globally to engineer diverse cell types and payloads, thereby accelerating the development of safe and effective treatments [3]. Investor Relations - Investors interested in the upcoming conference call must register online, with a recommendation to do so at least a day in advance [2]. - A live and archived webcast of the conference call will be available on the MaxCyte website [2].

Core Insights - MaxCyte, Inc. announced a restructuring plan aimed at aligning resources with strategic priorities, which includes a workforce reduction of approximately 34% and expected annualized savings of about $13.6 million [1][2][4] Financial Outlook - The company expects 2025 core revenue to be flat to down approximately 10% compared to 2024, with an anticipated $5 million in SPL program-related revenue for the full year [3] - Year-end cash, cash equivalents, and investments are projected to be at least $155 million [3] Strategic Initiatives - The workforce reduction is part of a broader initiative to reduce operating expenses, streamline the organizational structure, and accelerate the path toward profitability [2][4] - The CEO emphasized the importance of this decision for long-term success and indicated that further details on the financial impact and outlook for the remainder of 2025 will be provided in the upcoming third quarter earnings call [4]

Company Overview - MaxCyte, Inc. is a leading company focused on cell engineering, providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics [1][3] - The company has over 25 years of expertise in building best-in-class platforms and innovating solutions for the cell therapy market [3] Financial Results Announcement - MaxCyte will release its financial results for the first quarter of 2025 after the U.S. market closes on May 7, 2025 [1] - A conference call to discuss these financial results will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Registration - Investors interested in the conference call must register online, with a recommendation to do so at least a day in advance [2] - A live and archived webcast of the event will be available on the MaxCyte website [2]